818 related articles for article (PubMed ID: 32816087)
1. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
3. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract][Full Text] [Related]
4. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
5. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
7. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO; Hong J; Yoon AR
Front Immunol; 2022; 13():953410. PubMed ID: 36091031
[TBL] [Abstract][Full Text] [Related]
8. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.
Wang L; Chard Dunmall LS; Cheng Z; Wang Y
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640930
[TBL] [Abstract][Full Text] [Related]
9. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
[TBL] [Abstract][Full Text] [Related]
11. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R
Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246
[TBL] [Abstract][Full Text] [Related]
13. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
Oh CM; Chon HJ; Kim C
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
[TBL] [Abstract][Full Text] [Related]
14. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
15. Virotherapy: From single agents to combinatorial treatments.
Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
[TBL] [Abstract][Full Text] [Related]
16. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
17. Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.
Scott EM; Duffy MR; Freedman JD; Fisher KD; Seymour LW
Macromol Biosci; 2018 Jan; 18(1):. PubMed ID: 28902983
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer.
Zhang Y; Li Y; Chen K; Qian L; Wang P
J Cancer Res Ther; 2022 Sep; 18(5):1247-1255. PubMed ID: 36204869
[TBL] [Abstract][Full Text] [Related]
19. Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy.
Wang S; Wei J
Int J Cancer; 2022 Nov; 151(10):1654-1662. PubMed ID: 35633046
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
